25198-95-2

Basic information

• Product Name: 5-PYRIMIDINEMETHANAMINE
• Synonyms: 5-PYRIMIDINEMETHANAMINE;5-Pyrimidinemethanamine (9CI);C-Pyrimidin-5-yl-methylamine;5-Aminomethylpyrimidine;(PyriMidin-5-ylMethyl)aMine;5-AMinoMethyl pyriMidine (HCl salt)
• CAS NO: 25198-95-2
• Molecular Formula: C5H7N3
• Molecular Weight: 109.13
• Product Categories: PYRIMIDINE;Heterocyclic Compounds;Heterocycles;Heterocycle-Pyrimidine series
• Mol File: 25198-95-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 224.3 °C at 760 mmHg
• Flash Point: 112.1 °C
• Appearance: Low-melting yellow solid
• Density: 1.138 g/cm³
• Vapor Pressure: 0.0918mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility: DMSO, Methanol
• PKA: 7.89±0.29(Predicted)
• CAS DataBase Reference: 5-PYRIMIDINEMETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PYRIMIDINEMETHANAMINE(25198-95-2)
• EPA Substance Registry System: 5-PYRIMIDINEMETHANAMINE(25198-95-2)

Safety Data

• Hazardous Substances Data: 25198-95-2(Hazardous Substances Data)

Usage

Uses

5-Pyrimidinemethanamine (cas# 25198-95-2) is a compound useful in organic synthesis.

InChI:InChI=1/C5H7N3/c6-1-5-2-7-4-8-3-5/h2-4H,1,6H2

Upstream product

• 101346-02-5 5-pyrimidinylmethyl chloride 
• 10070-92-5 pyrimidine-5-carbaldehyde 
• 25193-95-7 5-(hydroxymethyl)pyrimidine 

Downstream Products

• 1185165-49-4 C₁₈H₁₅N₃ 
• 1439358-06-1 C₁₈H₁₆N₄O₃S 
• 1568916-86-8 C₂₁H₁₉N₅O 
• 1568916-46-0 C₁₅H₁₄N₂ 

Relevant articles and documents

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):